SNAP Message Board - Msg: 15975695

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNAP

SNAP 7.795

+2.8%

3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (103)	6/21/2001 11:42:44 AM
From: Biotech Jim	Read Replies (1) of 124

Just to add a couple of notes to the MCH receptor arena. SNAP was issued two US patents on the MCH receptor 1, 1 for the rat and the other for the human. Also, SKB, now GSK, published a JBC paper a few weeks ago on the second MCH receptor. (Sorry I don't have the reference or the issued US PTO numbers, but I am away from my home and work computer at this time.) I feel that the patents can be extremely useful if they are of sufficient breadth that results in a great barrier to entry. On the other hand, restricted receptor patents may not be that useful in the long run. What seems in my mind to be of the greatest value are composition of matter patents for modulatory agents at those receptors. Takeda has a couple of patents pending on MCH receptor 1 compounds. I'm sure others are in the hunt as well. BJ

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next